Compare Magle Chemoswed Holding AB with Similar Stocks
Dashboard
1
Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.26 times
- Poor long term growth as Net Sales has grown by an annual rate of 14.24% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.26 times
- The company has been able to generate a Return on Capital Employed (avg) of 1.78% signifying low profitability per unit of total capital (equity and debt)
- OPERATING CASH FLOW(Y) Lowest at SEK -80.38 MM
- PRE-TAX PROFIT(Q) At SEK 2.94 MM has Fallen at -72.56%
- NET PROFIT(Q) At SEK 3.14 MM has Fallen at -67.22%
2
Risky -
3
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
SEK 156 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.59
-5.00%
0.29
Revenue and Profits:
Net Sales:
71 Million
(Quarterly Results - Sep 2025)
Net Profit:
3 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-75.23%
0%
-75.23%
6 Months
-77.93%
0%
-77.93%
1 Year
-87.01%
0%
-87.01%
2 Years
-85.74%
0%
-85.74%
3 Years
-84.16%
0%
-84.16%
4 Years
-84.89%
0%
-84.89%
5 Years
-89.19%
0%
-89.19%
Magle Chemoswed Holding AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
14.24%
EBIT Growth (5y)
-162.25%
EBIT to Interest (avg)
-0.07
Debt to EBITDA (avg)
3.26
Net Debt to Equity (avg)
0.44
Sales to Capital Employed (avg)
0.56
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.78%
ROE (avg)
4.19%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.80
EV to EBIT
-35.00
EV to EBITDA
20.15
EV to Capital Employed
0.86
EV to Sales
2.41
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2.47%
ROE (Latest)
-3.81%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Bearish
Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
71.50
64.60
10.68%
Operating Profit (PBDIT) excl Other Income
31.70
12.10
161.98%
Interest
15.70
3.10
406.45%
Exceptional Items
0.00
0.00
Consolidate Net Profit
3.10
9.60
-67.71%
Operating Profit Margin (Excl OI)
259.20%
-9.70%
26.89%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 10.68% vs 77.96% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is -67.71% vs 1,820.00% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
236.00
170.40
38.50%
Operating Profit (PBDIT) excl Other Income
44.60
23.10
93.07%
Interest
11.30
3.20
253.12%
Exceptional Items
0.00
0.00
Consolidate Net Profit
11.90
12.20
-2.46%
Operating Profit Margin (Excl OI)
37.90%
58.50%
-2.06%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 38.50% vs 16.95% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -2.46% vs 34.07% in Dec 2023
About Magle Chemoswed Holding AB 
Magle Chemoswed Holding AB
Pharmaceuticals & Biotechnology
Magle Chemoswed Holding AB is a contract development manufacturing organization. The Company is located in Malmo, Sweden. It provides development and manufacturing services to healthcare companies as well as innovating and supplying new products based on the Company proprietary technology platform.






